These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 33169916)

  • 21. Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline.
    Lantero Rodriguez J; Karikari TK; Suárez-Calvet M; Troakes C; King A; Emersic A; Aarsland D; Hye A; Zetterberg H; Blennow K; Ashton NJ
    Acta Neuropathol; 2020 Sep; 140(3):267-278. PubMed ID: 32720099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
    Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
    Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
    Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
    Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome.
    Tatebe H; Kasai T; Ohmichi T; Kishi Y; Kakeya T; Waragai M; Kondo M; Allsop D; Tokuda T
    Mol Neurodegener; 2017 Sep; 12(1):63. PubMed ID: 28866979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease.
    Chatterjee P; Pedrini S; Ashton NJ; Tegg M; Goozee K; Singh AK; Karikari TK; Simrén J; Vanmechelen E; Armstrong NJ; Hone E; Asih PR; Taddei K; Doré V; Villemagne VL; Sohrabi HR; Zetterberg H; Masters CL; Blennow K; Martins RN
    Alzheimers Dement; 2022 Jun; 18(6):1141-1154. PubMed ID: 34494715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease.
    Chen SD; Huang YY; Shen XN; Guo Y; Tan L; Dong Q; Yu JT;
    Transl Psychiatry; 2021 Jun; 11(1):356. PubMed ID: 34120152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Two Analytical Platforms in Cerebrospinal Fluid Biomarkers for the Classification of Alzheimer's Disease Spectrum with Amyloid PET Imaging.
    Lim HJ; Park JE; Kim BC; Choi SM; Song MK; Cho SH; Seo HJ; Kim J; Song HC; Choi KY; Lee JJ; Kim HW; Ha JM; Song WK; Park SG; Lee JS; Lee KH
    J Alzheimers Dis; 2020; 75(3):949-958. PubMed ID: 32390627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile.
    Milà-Alomà M; Shekari M; Salvadó G; Gispert JD; Arenaza-Urquijo EM; Operto G; Falcon C; Vilor-Tejedor N; Grau-Rivera O; Sala-Vila A; Sánchez-Benavides G; González-de-Echávarri JM; Minguillon C; Fauria K; Niñerola-Baizán A; Perissinotti A; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Suárez-Calvet M; Molinuevo JL;
    Alzheimers Res Ther; 2021 Jul; 13(1):134. PubMed ID: 34315519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation and application of semi-synthetic p-Tau181 calibrator for immunoassay calibration.
    Liu L; Cai Y; Lauro BM; Meunier AL; Chhatwal J; Selkoe DJ
    Biochem Biophys Res Commun; 2022 Jun; 611():85-90. PubMed ID: 35483223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
    Koychev I; Hofer M; Friedman N
    J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later.
    Nägga K; Gustavsson AM; Stomrud E; Lindqvist D; van Westen D; Blennow K; Zetterberg H; Melander O; Hansson O
    Neurology; 2018 Jan; 90(1):e73-e81. PubMed ID: 29196581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease.
    Guo JP; Arai T; Miklossy J; McGeer PL
    Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1953-8. PubMed ID: 16446437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease.
    Fortea J; Vilaplana E; Alcolea D; Carmona-Iragui M; Sánchez-Saudinos MB; Sala I; Antón-Aguirre S; González S; Medrano S; Pegueroles J; Morenas E; Clarimón J; Blesa R; Lleó A;
    Ann Neurol; 2014 Aug; 76(2):223-30. PubMed ID: 24852682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subthreshold Amyloid Predicts Tau Deposition in Aging.
    Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ
    J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
    Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
    J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOEɛ4 Carriers.
    Starks EJ; Patrick O'Grady J; Hoscheidt SM; Racine AM; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Puglielli L; Asthana S; Dowling NM; Gleason CE; Anderson RM; Davenport-Sis NJ; DeRungs LM; Sager MA; Johnson SC; Bendlin BB
    J Alzheimers Dis; 2015; 46(2):525-33. PubMed ID: 25812851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tau proteins in blood as biomarkers of Alzheimer's disease and other proteinopathies.
    Verde F
    J Neural Transm (Vienna); 2022 Feb; 129(2):239-259. PubMed ID: 35175385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.